Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Real-time Estimate Cboe BZX  -  12:52 2022-09-28 pm EDT
9.975 USD   +5.22%
07:16aAlx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

08/11/2022 | 07:00am EDT

ALX Oncology Holdings Inc. announced the initiation of a Phase 2 investigator-sponsored study of evorpacept, a next generation CD47 blocker, in combination with ERBITUX® (cetuximab) and KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with refractory microsatellite stable metastatic colorectal cancer (“mCRC”) who have progressed on at least two lines of systemic therapy. This is an open-label, multi-center, single-arm phase 2 clinical trial (NCT05167409). Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, will respectively provide ERBITUX and KEYTRUDA to support this study.

This trial is being co-led by Wells Messersmith, M.D., Professor and Head of Medical Oncology at the University of Colorado Cancer Center and Director of the Academic GI Cancer Consortium (“AGICC”), and Robert Lentz, M.D., Assistant Professor of Medical Oncology at the University of Colorado Cancer Center. AGICC brings together a world class team of institutions and investigators to design and rapidly complete clinical trials in gastrointestinal cancers. The study is being managed by Criterium Inc., a full-service contract research organization dedicated to providing efficiency and expertise in clinical trial services.


© S&P Capital IQ 2022
All news about ALX ONCOLOGY HOLDINGS INC.
07:16aAlx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
08/26UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
08/15Alx Oncology : Corporate Presentation
PU
08/15ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu ..
MT
08/15ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
GL
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -126 M - -
Net cash 2022 247 M - -
P/E ratio 2022 -3,14x
Yield 2022 -
Capitalization 386 M 386 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 52
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,48 $
Average target price 38,13 $
Spread / Average Target 302%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-55.89%386
GILEAD SCIENCES, INC.-13.74%78 498
REGENERON PHARMACEUTICALS, INC.10.05%74 302
VERTEX PHARMACEUTICALS29.66%73 024
BIONTECH SE-49.46%31 665
WUXI APPTEC CO., LTD.-39.08%29 141